Two levels of stenosis. The average numbers of injection per patient was 1.9 (range, 1 to 3 injection per patient). There had been no key complications reported from sufferers after the injection procedures. There have been three individuals who seasoned worsening leg pains after injections but these symptoms resolved spontaneously soon after a few days. 1. Comparison of pre-injection and post-injection The 4 outcome measurements: VAS, Roland 5-point discomfort scale, standing tolerance and walking tolerance of pre-injection had been compared with post-injection at two weeks, six weeks, three months, and 12 months. Meanwhile, the patient satisfaction scale at 2 weeks post-injection wasAsian Spine Journalcompared with 6 weeks, 3 months, and 12 months postinjection as shown in Table 2. There have been significant decreases in VAS scores amongst pre-injection and post-injection at two weeks, 6 weeks, 3 months and 12 months (p0.001). The Roland 5-point pain scale between pre-injection and post-injection had been substantially enhanced at two weeks and 6 weeks (p0.001) respectively but were not considerably distinct from the pre-injection scores at three months and 12 months (p=0.09 and p=0.091, respectively). For standing tolerance and walking tolerance, the substantial distinction was identified only amongst pre-injection and post-injection at 2 weeks (p0.001). At 6 weeks, 3 months and 12 months, there have been no important improvements in standing tolerance and walking tolerance, (p0.05). For the patient satisfaction scale, there have been considerable decreases in satisfaction between post-injection at 2 weeks and post-injection at 6 weeks, 3 months and 12 months (p=0.02, p=0.002, and p=0.005, respectively). two. Comparison of 1 amount of stenosis with two of levels stenosis Evaluation of variance was utilised for comparing the outcomeOutcomes of fluoroscopically guided 123 measurements following TFESI of 1 level stenosis DLS sufferers with two level stenosis DLS sufferers as shown in Table three.2422999-74-2 uses The VAS of each groups post-injection (two weeks, six weeks, three months, and 12 months) had been drastically lower than pre-injection (p0.001). When compared amongst groups, the VAS of one particular level of stenosis DLS patients post-injection was significantly reduce than the VAS of two level of stenosis DLS individuals (p=0.012) as shown in Fig. 2. The Roland 5-point discomfort scale of 1 level of steno-sis DLS patients post-injection (two weeks, 6 weeks, and 12 months) have been drastically reduced than pre-injection (p0.001) whilst in two levels of stenosis DLS sufferers, the Roland 5-point pain scale post-injection was signifi-cantly reduced than pre-injection (p=0.001) at two weeks. When compared involving groups, the Roland 5-point pain scale of a single amount of stenosis DLS patients post-injection was significantly reduced than the Roland 5-point pain scale of two levels of stenosis DLS individuals (p=0.2-(Oxetan-3-yl)acetic acid web 012) as shown in Fig.PMID:24631563 three. The standing tolerance of 1 level of stenosis DLS sufferers post-injection at two weeks was considerably larger than pre-injection (p0.001) when in two levels of stenosis DLS sufferers, there was no substantial variations inside the standing tolerance involving pre-injection and post-in-7 6Means of VAS4 3 2 1Stenosis 1 level Stenosis 2 levelsPre-injection2 wk6 wk3 mo12 moFig. 2. Line graph displaying the VAS of a single degree of stenosis DLS individuals and two levels of stenosis DLS individuals over time. There was a considerable difference (p =0.0124) involving these two groups. VAS, visual analog scale; DLS, lumbar spondylolisthesis.124 Chaiwat Kraiwatt.
